Trial reportLeukemia2017
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.
Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.Blood advances · 2020Pooled it
- Review
- Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.Nature reviews. Clinical oncology · 2025Review
- Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions.Blood research · 2025Review
- Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing-Based Clonality Testing in B-Cell and Plasma Cell Neoplasms.The Journal of molecular diagnostics : JMD · 2024Article
- [Minimal residual disease assessment and progress in multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Review
- Article
- NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.Cancers · 2022Article
- Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting.Frontiers in oncology · 2022Review
- Review
- MRD Assessment in Multiple Myeloma: Progress and Challenges.Current hematologic malignancy reports · 2021Review
- Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma.Exploration of targeted anti-tumor therapy · 2021Review
- Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications.Frontiers in oncology · 2021Review
- Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.Frontiers in immunology · 2021Article
- Erratum: Mina, R.; et al. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives.Journal of clinical medicine · 2020Article
- Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma.Blood advances · 2020Article
- Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives.Journal of clinical medicine · 2020Review
- Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.Blood advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.